Drug intelligence / Profile preview

YMN-136

Development stage: Phase 1
Lead developer: West China Hospital of Sichuan University
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

YMN-136 is an investigational therapeutic cancer vaccine developed by West China Hospital for the treatment of advanced colorectal cancer. It is specifically being studied in patients with liver metastases who have progressed after third-line therapy. As a biological intervention, YMN-136 is designed to stimulate the host immune system to recognize and attack tumor cells. The vaccine is currently undergoing evaluation in a prospective Phase I clinical trial (NCT06144307) to determine its safety profile, maximum tolerated dose (MTD), and preliminary efficacy. The treatment regimen typically involves a prime immunization phase consisting of four intramuscular injections administered approximately every three weeks.

Other names: YMN-136 vaccineYMN136 vaccineYMN 136 vaccine

Beyond the preview

Go deeper on YMN-136.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YMN-136.

Explore the full profile